Last reviewed · How we verify
NCT06194864
Drug Interaction Study
Phase 1 trial testing Itraconazole in Drug Interaction in 45 participants. Completed in 22 May 2024.
14 May 2024
Quick facts
| Lead sponsor | Emalex Biosciences Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 45 |
| Start date | 18 January 2024 |
| Primary completion | 14 May 2024 |
| Estimated completion | 22 May 2024 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Itraconazole — full drug profile →
- rifampicin (Rifampicin) — full drug profile →
- Ecopipam — full drug profile →
Conditions studied
- Drug Interaction — all drugs for Drug Interaction →
Sponsor
Emalex Biosciences Inc. — full company profile →
Who can join
Adults 18 to 55, any sex, with Drug Interaction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single center, 2-Part, Phase 1, open-label, fixed-sequence, drug-drug interaction study designed to compare the PK of ecopipam when administered alone and in combination with itraconazole (Part 1) or rifampicin (Part 2) in healthy subjects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06194864
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Itraconazole
Trials testing the same drug.
- NCT07341672 — A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itrac · Phase 1 · not yet recruiting
- NCT06732388 — Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's E · Phase 2 · not yet recruiting
- NCT07449390 — Drug-drug Interaction Trial of AP31969 and Carbamazepine or Itraconazole · Phase 1 · not yet recruiting
- NCT07435194 — A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affects Midazo · Phase 1 · recruiting
- NCT07308652 — A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 764198 in the Blood · Phase 1 · completed
Other recruiting trials for Drug Interaction
Currently open trials in the same condition.
- NCT06717581 — Variation in Drug Interactions in People With HIV (PLWH) Aged 60 Years and Older. · recruiting
- NCT05512169 — Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia · recruiting
- NCT04593680 — Assessment of Drug-drug Interactions Between Masculinizing Hormone Therapy and Antiretroviral Agents Concomitantly for P · NA · active not recruiting
- NCT04590417 — Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomit · NA · active not recruiting
Other Emalex Biosciences Inc. trials
Trials by the same sponsor.
- NCT06669091 — Food-effect Study of Ecopipam Pharmacokinetics · Phase 1 · completed
- NCT05841160 — Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization · Phase 1 · completed
- NCT05615220 — Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults · Phase 3 · completed
- NCT05334108 — Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug · Phase 1 · completed
- NCT04902105 — Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06194864 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Emalex Biosciences Inc.
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06194864.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing